^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Esophageal Adenocarcinoma

    Related cancers:
    1d
    Induction FLOT With CROSS CRT for Esophageal Cancer (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, University of Colorado, Denver | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    carboplatin • docetaxel • oxaliplatin
    1d
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread (clinicaltrials.gov)
    P1/2, N=768, Recruiting, Boehringer Ingelheim | N=582 --> 768 | Trial completion date: Sep 2029 --> Jan 2029 | Trial primary completion date: Sep 2029 --> Jan 2029
    Enrollment change • Trial completion date • Trial primary completion date
    |
    5-fluorouracil • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • leucovorin calcium • Ziihera (zanidatamab-hrii) • Hernexeos (zongertinib)
    3d
    Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Massachusetts General Hospital
    New P2 trial
    |
    docetaxel • 5-fluorouracil • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • domvanalimab (AB154)
    3d
    Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=40, Recruiting, Roswell Park Cancer Institute | Trial completion date: Mar 2026 --> Mar 2029 | Trial primary completion date: Mar 2026 --> Mar 2029
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • oxaliplatin • leucovorin calcium • fluorouracil topical
    3d
    First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=155, Recruiting, Plexium, Inc.
    New P1 trial • First-in-human
    4d
    MORPHEUS-EC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (clinicaltrials.gov)
    P1/2, N=214, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | N=410 --> 214
    Trial completion • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    HER-2 negative • HER-2 expression
    |
    cisplatin • Tecentriq (atezolizumab) • paclitaxel • 5-fluorouracil • Cotellic (cobimetinib) • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium • tiragolumab (RG6058) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide)
    4d
    A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=6, Completed, Seagen, a wholly owned subsidiary of Pfizer | Active, not recruiting --> Completed
    Trial completion
    |
    sigvotatug vedotin (PF-08046047)
    4d
    Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) (clinicaltrials.gov)
    P1/2, N=210, Recruiting, Merck Sharp & Dohme LLC | N=90 --> 210
    Enrollment change
    |
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    Keytruda (pembrolizumab) • paclitaxel • Cyramza (ramucirumab) • patritumab deruxtecan (U3-1402) • Jiataile (sacituzumab tirumotecan)
    4d
    HERIZON-GEA-01: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (clinicaltrials.gov)
    P3, N=920, Active, not recruiting, Jazz Pharmaceuticals | Trial completion date: May 2026 --> Jul 2027 | Trial primary completion date: Dec 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression
    |
    Herceptin (trastuzumab) • cisplatin • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • Ziihera (zanidatamab-hrii)
    4d
    OLIGOMETS: Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels (clinicaltrials.gov)
    P2, N=54, Not yet recruiting, Yale University
    New P2 trial • Circulating tumor DNA
    7d
    LB1908-1001: Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=56, Active, not recruiting, Legend Biotech USA Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    LB1908
    8d
    A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=260, Not yet recruiting, IDEAYA Biosciences
    New P1 trial
    |
    IDE397